Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: The nature, mechanisms, consequences and potential treatment

Nephrology Dialysis Transplantation

Volumn 31, Issue 5, 2016, Pages 737-746

  Vaziri, Nosratola D ^a   Zhao, Ying Yong ^a   Pahl, Madeleine V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiovascular disease; end stage renal disease; microbiome; oxidative stress; uremia

Indexed keywords

ACTIVATED CARBON; ALPHA GLYCOSIDASE; GLYCOSIDASE; LIPOPOLYSACCHARIDE; PROBIOTIC AGENT; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UREA;

ARTICLE; BIOCHEMISTRY; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DYSBIOSIS; END STAGE RENAL DISEASE; ENDOTOXEMIA; ENTEROPATHY; ENZYME INHIBITION; EPITHELIAL BARRIER STRUCTURE; HIGH FIBER DIET; HUMAN; INTESTINE ABSORPTION; INTESTINE EDEMA; INTESTINE FLORA; INTESTINE ISCHEMIA; MEMBRANE; MICROBIAL COMMUNITY; MICROBIAL GENETICS; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TIGHT JUNCTION; UREMIA; ANIMAL; CELL MEMBRANE PERMEABILITY; CHRONIC KIDNEY FAILURE; COMPLICATION; EPITHELIUM; INFLAMMATION; INTESTINE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CELL MEMBRANE PERMEABILITY; EPITHELIUM; HUMANS; INFLAMMATION; INTESTINES; RENAL INSUFFICIENCY, CHRONIC; TIGHT JUNCTIONS;

EID: 84965096659     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv095     Document Type: Article

References (102)

1. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003; 12: 593-598
2. Himmelfarb J, Stenvinkel P, Ikizler TA et al. the elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
3. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99
4. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469-473
5. Cachofeiro V, Goicochea M, de Vinuesa SG et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; 111: S4-S9
6. Stenvinkel P. Inflammation in end-stage renal disease-a fire that burns within. Contrib Nephrol 2005; 149: 185-199
7. Kato S, Chmielewski M, HondaHet al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533
8. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C et al. the pathogenesis of sepsis. Annu Rev Pathol 2011; 6: 19-48
9. Heine GH, Ortiz A, Massy ZA et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012; 8: 362-369
10. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end stage renal disease. Kidney Int 2007; 71: 167-172
11. Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to assess. Clin J Am Soc Nephrol 2009; 4: S56-S63
12. Kim HJ,Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671
13. Kim HJ, Sato T, Rodriguez-Iturbe B et al. Role of intrarenal angiotensin system activation, oxidative stress, inflammation and impaired Nrf2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther 2011; 337: 583-590
14. Aminzadeh MA, Nicholas SB, Norris KC et al. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 2013; 28: 2038-2045
15. Ruiz S, Pergola PE, Zager RA et al. Targeting the transcription factor Nrf2 activation to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013; 83: 1029-1041
16. Vaziri ND. Epidemic of iron overload in dialysis population caused by intravenous iron products: A plea for moderation. Am J Med 2012; 125: 951-952
17. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
18. Fishbane S, Matthew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014; 29: 255-259
19. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638
20. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-546
21. Quin J, Li R, Raes J et al. Ahuman gut microbial gene catalogue established by metagenomics sequencing. Nature 2010; 464: 59-65
22. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180
23. Bourlioux P,Koletzko B,Guarner F et al. the intestine and itsmicroflora are partners for the protection of the host: report on the Danone Symposium 'the intelligent intestine', held in Paris. Am J Clin Nutr 2003; 78: 675-683
24. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115-1118
25. Savage DC. Gastrointestinal microflora in mammalian nutrition. Annu Rev Nutr 1986; 6: 155-178
26. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283-307
27. Metges CC. Contribution of microbial amino acids to amino acid homeostasis of the host. J Nutr 2000; 130: 1857S-11864S
28. Burkholder PR, McVeigh I. Synthesis of vitamins by intestinal bacteria. Proc Natl Acad Sci USA 1942; 28: 285-289
29. Cerf-Bensussan N, Eberl G. the dialog between microbiota and the immune system: shaping the partners through development and evolution. Semin Immunol 2012; 24: 1-2
30. Tlaskalova-Hogenova H, Stepankova R, Kozakova H et al. the role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110-120
31. Frank DN, St Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785
32. Brugman S, Klatter FA, Visser JT et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 2006; 49: 2105-2108
33. Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med (Maywood) 2004; 229: 586-597
34. Bäckhed F, Manchester JK, Semenkovich CF et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104: 979-984
35. Isolauri E, Kalliomäki M, Laitinen K et al. Modulation of the maturing gut barrier and microbiota: A novel target in allergic disease. Curr Pharm Des 2008; 14: 1368-1375
36. Coppo R. the intestine-renal connection in IgA nephropathy. Nephrol Dial Transplant 2015; 30: 360-366
37. Kang JY. the gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-268
38. Vaziri ND, Dure-Smith B, Miller R et al. Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985; 80: 608-611
39. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995; 6: 1313-1317
40. Hatch M, Vaziri ND. Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci 1994; 86: 511-516
41. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrology 1994; 5: 1339-1343
42. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int 2013; 83: 308-315
43. Wong J, Piceno YM, DeSantis TZ et al. Expansion of urease and uricasecontaining, indole-and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol 2014; 39: 230-237
44. Simenhoff ML, Saukkonen JJ, Burke JF et al. Bacterial populations of the small intestine in uremia. Nephron 1978; 22: 63-68
45. Strid H, Simren M, Stotzer PO et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003; 67: 129-137
46. Aronov PA, Luo FJ, Plummer NS et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22: 1769-1776
47. Lewis GD, Wei R, Liu E et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008; 118: 3503-3512
48. Rak K, Rader DJ. the diet-microbemorbid union. Nature 2011; 472: 40-41
49. Koeth RA,Wang Z, Levison BS et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-585
50. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63
51. Bell JD, Lee JA, Lee HA et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096: 101-107
52. Bain MA, Faull R, Fornasini G et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006; 21: 1300-1304
53. Meinardi S, Jin KB, BlakeDR et al.Novel gaseous breath and fecal biomarkers of CKD. Biochim Biophys Acta-Gen Subjects 2012; 1830: 2531-2537
54. Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013; 37: 1-6
55. Lau WL, Liu S, Pahlevan S et al. Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption. Dig Dis Sci 2014; PMID: 25399330 [Epub ahead of print]
56. Gonçalves S, Pecoits-Filho R, Perreto S et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006; 21: 2788-2794
57. Szeto CC, Kwan BC, Chow KM et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 431-436
58. Feroze U, Kalantar-Zadeh K, Sterling KA et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012; 22: 317-326
59. Raj DS, Carrero JJ, Shah VO et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis 2009; 54: 1072-1080
60. Bossola M, Sanguinetti M, Scribano D et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 379-385
61. Wang F, Jiang H, Shi K et al. Gut bacterial translocation is associated with micro-inflammation in end-stage renal disease patients. Nephrology (Carlton) 2012; 17: 733-738
62. Wang F, Zhang P, Jiang H et al. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci 2012; 57: 2856-2862
63. de Almeida DJ, de Aguilar-Nascimento JE, Nascimento M et al. Bacterial translocation in experimental uremia. Urol Res 2004; 32: 266-270
64. Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59: 2109-2117
65. Vaziri ND. Role of the gut microbial translocation in the pathogenesis of systemic inflammation in patients with end-stage renal disease. Dig Dis Sci 2014; 59: 2020-2022
66. Andrade-Oliveira V, Amano MT, Correa-Costa M et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 2015; pii: ASN.2014030288
67. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809
68. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000; 279: G851-G857
69. Magnusson M, Magnusson KE, Sundqvist Tet al. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low-and high protein diets. Nephron 1990; 56: 306-311
70. Magnusson M, Magnusson KE, Sundqvist T et al. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991; 32: 754-759
71. Ritz E. Intestinal-renal syndrome: mirage or reality? Blood Purif 2011; 31: 70-76
72. Vaziri ND, Yuan J, Rahimi A et al. Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012; 27: 2686-2693
73. Vaziri ND, Yuan J, Nazertehrani S et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013; 38: 99-103
74. Vaziri ND, Goshtasby N, Yuan J et al. Uremic human plasma degrades intestinal epithelial barrier structure and function. Am J Nephrol 2012; 36: 438-443
75. Peschel T, Schönauer M, Thiele H et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003; 5: 609-614
76. Sandek A, Rauchhaus M, Anker SD et al. the emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008; 11: 632-639
77. Sandek A, Bauditz J, Swidsinski A et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-1569
78. Pijls KE, Jonkers DM, Elamin EE et al. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int 2013; 33: 1457-1469
79. Chang M, Kistler EB, Schmid-Schönbein GW. Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall. Shock 2012; 37: 297-305.
80. Rossi UG, Petrocelli F, Seitun S et al. Nonocclusive mesenteric ischemia in a dialysis patient with extensive vascular calcification. Am J Kidney Dis 2012; 60: 843-846
81. Gerson LB. the presence of hemodialysis has been associated with GI hemorrhage, likely owing to intermittent usage of heparin for dialysis treatments and the presence of uremia-induced platelet dysfunction. Am J Med 1985; 79: 552-559
82. Mafra D, Lobo JC, Barros AF et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in CKD. Future Microbiol 2014; 9: 399-410
83. Mitch WE, Walser M, Steinman TI et al. the effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med 1984; 311: 623-629
84. Smith PM, Howitt MR, Panikov N et al. the microbial metabolites, shortchain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573
85. Vaziri ND, PahlMV, Crum A et al. Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22: 149-156
86. Hendrikx TK, van Gurp EA, Mol WM et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009; 24: 1969-1978
87. Vaziri ND, Liu S, Lau WL et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014; 9: e114881
88. Sirich TL, Plummer NS, Gardner CD et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9: 1603-1610
89. Evenepoel P, Bammens B, Verbeke K et al. Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. Kidney Int, 2006; 70, 192-198
90. Goto S, Yoshiya K, Kita T et al. Uremic toxins and oral adsorbents. Ther Apher Dial 2011; 15: 132-134
91. Kikuchi K, Itoh Y, Tateoka R et al. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 2010; 878: 2997-3002
92. Meyer TW, Hostetter TH. Uremic solutes from colon microbes. Kidney Int 2012; 81: 949-954
93. Niwa T. Recent progress in the analysis of uremic toxins by mass spectrometry. J Chromatogr B 2009; 877: 2600-2606
94. Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-tomesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. J Ren Nutr 2012; 22: 176-180
95. Shibahara H, Shibahara N. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010; 23: 535-540
96. Nakamura T, Sato E, Fujiwara N et al. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 2011; 60: 260-264
97. Ito S, Higuchi Y, Yagi Y et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013; 93: 837-845
98. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011; 15: 120-124
99. Vaziri ND, Yuan J, Khazaeli M et al. Oral activated charcoal adsorbent (AST-120) ameliorates CKD-induced intestinal epithelial barrier disruption and systemic inflammation. Am J Nephrol 2013; 37: 518-525
100. Ranganathan N, Ranganathan P, Friedman EA et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27: 634-647
101. Miranda Alatriste PV, Urbina AR, Gomez Espinosa COet al. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 2014; 29: 582-590
102. Natarajan R, Pechenyak B, Vyas U et al. Randomized controlled trial of strain-specific probiotic formulation (renadyl) in dialysis patients. Biomed Res Int 2014; 2014: 568571